+ Follow GLIMEPIRIDE Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 321958
[Title] => Economical drug available for diabetics
[Summary] => Diabetic patients will now have an easier access to a drug that would help decrease their blood sugar and reduce the risk of complications brought about by the condition.
Therapharmas brand of glimepiride which was introduced late last year, is now part of the antidiabetic regimen of many Filipino patients with type 2 diabetes.
[DatePublished] => 2006-02-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 319658
[Title] => Glimepiride shown to be effective, safe for diabetes control
[Summary] => Glimepiride has been shown to be an effective and safe medicine in lowering blood sugar, providing a precise blood sugar control without the side-effects often associated with other drugs of the same class known as sulfonylureas.
[DatePublished] => 2006-02-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 306158
[Title] => Therapharma launches pharmacoeconomic glimepiride for diabetes
[Summary] => People with diabetes will now have better access to a medicine that would help lower their blood sugar and reduce the risk of complications brought about by the condition.
Therapharma, a division of United Laboratories, recently launched its brand of glimepiride, an oral medicine belonging to a class of blood sugar-lowering drugs called sulfonylurea.
Glimepiride is used in type II diabetes, the most common type of diabetes that is found in most patients with diabetes.
[DatePublished] => 2005-11-10 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
GLIMEPIRIDE
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 321958
[Title] => Economical drug available for diabetics
[Summary] => Diabetic patients will now have an easier access to a drug that would help decrease their blood sugar and reduce the risk of complications brought about by the condition.
Therapharmas brand of glimepiride which was introduced late last year, is now part of the antidiabetic regimen of many Filipino patients with type 2 diabetes.
[DatePublished] => 2006-02-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 319658
[Title] => Glimepiride shown to be effective, safe for diabetes control
[Summary] => Glimepiride has been shown to be an effective and safe medicine in lowering blood sugar, providing a precise blood sugar control without the side-effects often associated with other drugs of the same class known as sulfonylureas.
[DatePublished] => 2006-02-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 306158
[Title] => Therapharma launches pharmacoeconomic glimepiride for diabetes
[Summary] => People with diabetes will now have better access to a medicine that would help lower their blood sugar and reduce the risk of complications brought about by the condition.
Therapharma, a division of United Laboratories, recently launched its brand of glimepiride, an oral medicine belonging to a class of blood sugar-lowering drugs called sulfonylurea.
Glimepiride is used in type II diabetes, the most common type of diabetes that is found in most patients with diabetes.
[DatePublished] => 2005-11-10 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
February 16, 2006 - 12:00am
February 2, 2006 - 12:00am
November 10, 2005 - 12:00am